Assay design in the face of SARS-CoV-2 mutations

Stay up to date on what we’re doing around the latest SARS-CoV-2 mutations:
Learn more about the TaqPath COVID-19 tests:
Read our latest blogs around coronavirus:

It’s a known fact that viruses mutate all the time, and it was no surprise that SARS-CoV-2 was no exception. However, there are whole host of issues that arise when the impact of these mutations is global, and it involves a novel coronavirus crisis. The good news is that assay performance should not be impacted, and in the video below, Manoj Gandhi, Sr. Director of Medical Affairs at Thermo Fisher Scientific, discusses the company’s approach to infectious disease assay design. He mentions how the assay team was able to lean on their expertise with past outbreaks such as Zika, SARS and MERS during the onset of developing the coronavirus assay. This led to a design that embraces genomic conservation, redundancy and produces an assay that is specific and sensitive.

This video represents the most up-to-date information about SARS-CoV-2 variants as of January 14, 2021. Intended use and regulatory statements of products vary. For specific intended use and regulatory statements please refer to the Instructions for Use (IFU). Product availability by
country varies.